Invests in a diversified portfolio of T. Rowe Price stock and bond mutual funds. Adjusts asset allocation over time based on a target retirement date of 2040. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 77× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $349.7M a year. A small number, but proof the product has real buyers.
It pays out $1.43 per share each year — regular cash for whoever holds the stock.
A loss of $55.9M against $349.7M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.